Cydelic | Digital Solutions for Psychedelic Therapy

What We Do

Precision Biodata Capture and Analysis

Wearable Biosensors

We provide sleek biomedical grade wearable devices optimized for precision data gathering.

Real Time Data Capture

All of our devices provide real-time data streaming to our session monitoring console.

Data Analysis and Reporting

you get detailed reports from every session to track longitudinal changes in behavior.

Our Mission

Cydelic Provides a Digital Safety Net for Psychedelic Therapy with:

Therapist Training
Patient Screening and Baselining
Vital Signs Monitoring
Critical State Tracking
Programmable Warning Flags
Multi-Patient Monitoring
Remote Monitoring
Longitudinal Tracking
Customizable Reporting

Our Tech

Our Wearable Partner Devices Integrate with the Cydelic Platform

FitBit

EmotiBit

Neurosity

Flowtime

Viatom

Bitbrain

Milestones

Our Roadmap to Accelerating Psychedelic Therapy

Q1 2021

Hardware Research

Cydelic forms as an LLC and begins testing wearable hardware candidates for our session monitoring prototype. Significant biomarkers for exploration include EEG, heart activity, respiration, skin temperature, and emotional arousal.
Q2 2021

Hardware Partnership Agreements

Cydelic enters into partnership agreements with multiple vendors in the commercial biosensor space. Partnership agreements include access to device SDKs to allow Cydelic access to real-time monitoring options. Cydelic begins testing and benchmarking data output specifications for each device.
Q3 2021

Completion of Prototype

Cydelic delivers a functional prototype of the Session Monitoring Platform compatible with multiple hardware partners. Cydelic performs a demonstration of the session monitoring prototype for potential clinical partners, including real-time streaming of biodata for remote monitoring.
Q4 2021

Incorporation

Cydelic forms a Class C Corporation in Delaware and begins formation of advisory board. Cydelic files our first provisional patent for our proprietary Dose Response Predictor, and attends the Wonderland conference in Miami to meet with potential investors and clinical partners.
December 2021

Cydelic Enters into Agreement with Emyria

Cydelic signs letter of intent to support Emyria in upcoming phase 2B clinical trial of MDMA-assisted psychotherapy for PTSD. This study will be the first-ever psychedelic clinical trial to gather biodata from wearable devices throughout the entire course of months-long therapy.